BriaCell Therapeutics Corp. - Common Shares (BCTX)
4.1900
+0.00 (0.00%)
NASDAQ · Last Trade: Apr 22nd, 7:27 AM EDT
Detailed Quote
Previous Close
4.190
Open
-
Bid
4.100
Ask
4.440
Day's Range
N/A - N/A
52 Week Range
0.3510 - 7.870
Volume
1,630
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
1,085,674
Chart
About BriaCell Therapeutics Corp. - Common Shares (BCTX)
Briacell Therapeutics Corp is a biotechnology company focused on developing innovative immunotherapies to treat cancer, particularly breast cancer. The company specializes in creating personalized therapeutic approaches that harness the body’s immune system to target and eliminate cancer cells. Through its proprietary technology, Briacell aims to improve treatment outcomes for patients by enhancing the efficacy and safety of existing therapies, ultimately striving to bring new and effective cancer treatment options to the market. Their commitment to advancing cancer care is reflected in their rigorous research and clinical development efforts. Read More
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.
HR+ metastatic breast cancer patients treated with Bria-IMT plus check point inhibitors had a median overall survival of 17.3 months, exceeding the 14.4 months with Trodelvy in similar heavily pre-treated patients, the company said.
BriaCell Therapeutics and Recursion Pharmaceuticals are two biotech firms that may be poised for success in 2025; risk-tolerant investors might keep an eye out.
BriaCell (NASDAQ: BCTX, BCTXW) (TSX: BCT), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, has announced the pricing of a best-efforts public offering of 762,500 common shares, each at a public offering price of $4.00. The company expects $3.05 million in total gross proceeds from the offering, of which it intends to use the net for working capital, general corporate purposes, and the advancement of business objectives. Subject to the satisfaction of customary conditions, the offering is expected to close on Feb. 5, 2025. ThinkEquity is acting as the sole placement agent for the offering.
Bria-OTS is a next-generation, personalized advancement of BriaCell’s lead candidate, Bria-IMT, which is currently in a pivotal Phase 3 study for metastatic breast cancer.
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
BriaCell Therapeutics stock rises on positive Phase 2 trial results showing improved survival in late-stage metastatic breast cancer patients treated with Bria-IMT and an immune checkpoint inhibitor.
